Potactasol

The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy. 6). Posology When topotecan is used in combination with cisplatin, the full prescribing information for cisplatin should be consulted.

5 x 109/l, a platelet count of ≥ 100 x 109/l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary). 5 mg/m2 body surface area per day administered by intravenous infusion over 30 minutes daily for five consecutive days with a three week interval between the start of each course.

1). Subsequent doses Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary). g. G-CSF) or to reduce the dose to maintain neutrophil counts.

0 mg/m2/day if necessary). Doses should be similarly reduced if the platelet count falls below 25 x 109/l. 0 mg/m2/day and a further dose reduction was required to manage adverse effects. 75 mg/m2/day administered as a 30-minute intravenous infusion on days 1, 2 and 3.

Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose. This treatment schedule is repeated every 21 days for six courses or until progressive disease. 5 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).

g. G-CSF) or to reduce the dose to maintain neutrophil counts. 45 mg/m2/day if necessary). Doses should be similarly reduced if the platelet count falls below 25 x 109/l. Special populations Patients with renal impairment Monotherapy (ovarian and small cell lung carcinoma) There is insufficient experience with the use of topotecan in patients with severely impaired renal function (creatinine clearance <20 ml/min).

4). 4 Limited data indicate that the dose should be reduced in patients with moderate renal impairment. 75 mg/m2/day for five consecutive days. 5 mg/dl. 5 mg/dl, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation.

If cisplatin is discontinued, there are insufficient data regarding continuing monotherapy with topotecan in patients with cervical cancer. 5 mg/m2/day for five days every three weeks. A reduction in topotecan clearance was observed.

In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose limiting toxicity of topotecan monotherapy was found to be haematological. Toxicity was predictable and reversible.

There were no signs of cumulative haematological or non-haematological toxicity. The safety profile of topotecan when given in combination with cisplatin in the cervical cancer clinical studies is consistent with that seen with topotecan monotherapy.

The overall haematological toxicity is lower in patients treated with topotecan in combination with cisplatin compared to topotecan monotherapy, but higher than with cisplatin alone. Additional adverse events were seen when topotecan was given in combination with cisplatin, however, these events were seen with cisplatin monotherapy and were not attributable to topotecan.

The prescribing information for cisplatin should be consulted for a full list of adverse events associated with cisplatin use. The integrated safety data for topotecan monotherapy are presented below. Adverse reactions are listed below, by system organ class and absolute frequency (all reported events).

Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); 7 uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

4). 3 Reactions have been mild and have not generally required specific therapy. 4). The frequencies associated with the haematological and non-haematological adverse events listed below represent the adverse event reports considered to be related/possibly related to topotecan therapy.

5 x 109/l) during course 1 in 55 % of patients, with duration ≥ seven days in 20 % and overall in 77 % of patients (39 % of courses). In association with severe neutropenia, fever or infection occurred in 16 % of patients during course 1 and overall in 23 % of patients (6 % of courses).

2). As with other cytotoxic medicinal products, topotecan can cause severe myelosuppression. 8). 5 Topotecan-induced neutropenia can cause neutropenic colitis. Fatalities due to neutropenic colitis have been reported in clinical studies with topotecan.

In patients presenting with fever, neutropenia, and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered. 8). Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation and use of pneumotoxic substances and/or colony stimulating factors.

g. cough, fever, dyspnoea and/or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed. Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia.

g. if patients at increased risk of tumour bleeds are considered for therapy. 8). Accurate assessment of performance status at the time therapy is given is important, to ensure that patients have not deteriorated to PS 3. There is insufficient experience of the use of topotecan in patients with severely impaired renal function (creatinine clearance < 20 ml/min) or severely impaired hepatic function (serum bilirubin ≥ 10 mg/dl) due to cirrhosis.

2). 5 mg/m2/day for five days every three weeks. A reduction in topotecan clearance was observed. 2). e. essentially ‘sodium- free’.

5 x 109/l and/or a platelet count of < 100 x 109/l.